{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:24Z","timestamp":1792290744091,"version":"4.4.0"},"reference-count":108,"publisher":"The Korean Society of Anesthesiologists","issue":"3","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["anesth-pain-med.org"],"crossmark-restriction":true},"short-container-title":["Anesth Pain Med"],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:p>Dantrolene sodium (DS) was first introduced as an oral antispasmodic drug. However, in 1975, DS was demonstrated to be effective for managing malignant hyperthermia (MH) and was adopted as the primary therapeutic drug after intravenous administration. However, it is difficult to administer DS intravenously to manage MH. MH is life-threatening, pharmacogenomically related, and induced by depolarizing neuromuscular blocking agents or inhalational anesthetics. All anesthesiologists should know the pharmacology of DS. DS suppresses Ca2+ release from ryanodine receptors (RyRs). RyRs are expressed in various tissues, although their distribution differs among subtypes. The anatomical and physiological functions of RyRs have also been demonstrated as effective therapeutic drugs for cardiac arrhythmias, Alzheimer\u2019s disease, and other RyR-related diseases. Recently, a new formulation was introduced that enhanced the hydrophilicity of the lipophilic DS. The authors summarize the pharmacological properties of DS and comment on its indications, contraindications, adverse effects, and interactions with other drugs by reviewing reference articles.<\/jats:p>","DOI":"10.17085\/apm.22260","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T05:02:37Z","timestamp":1690347757000},"page":"220-232","update-policy":"https:\/\/doi.org\/10.17085\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Current clinical application of dantrolene sodium"],"prefix":"10.17085","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-8705","authenticated-orcid":true,"given":"Hong Seuk","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-6586","authenticated-orcid":true,"given":"Jae Moon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7403-4287","authenticated-orcid":true,"given":"Junyong","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-1477","authenticated-orcid":true,"given":"Tae-yun","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-6525","authenticated-orcid":true,"given":"Yong Beom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-1785","authenticated-orcid":true,"given":"Shofina","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2573","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/34.6.395"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1566524023362429"},{"key":"ref3","first-page":"381","volume-title":"Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands","author":"Riazi","year":"2014"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0310-1"},{"key":"ref5","first-page":"1400","volume-title":"The cytoprotective effects of dantrolene: a ryanodine receptor antagonist","author":"Inan","year":"2010"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24040728"},{"key":"ref7","first-page":"774","volume-title":"Early development, identification of mode of action, and use of dantrolene sodium: The role of Keith Ellis, Ph.D","author":"Pollock","year":"2017"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2918"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/cc2923"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1017\/s1481803500012598"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/47.1.62"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4097\/kja.d.18.00139"},{"key":"ref13","first-page":"147","volume-title":"A survey for prevention and treatment of malignant hyperthermia in Taiwan","author":"Yip","year":"2004"},{"key":"ref14","first-page":"773","volume-title":"[Stocks of dantrolene in anesthesia and intensive care units in Germany: nationwide online survey with 1673 participants]","author":"Pfenninger","year":"2017"},{"key":"ref15","first-page":"e201","volume-title":"Pennywise and a Pound foolish: the advantage of dantrolene nanosuspension (Ryanodex) in the treatment of malignant hyperthermia","author":"McAvoy","year":"2019"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/wad.0000000000000076"},{"key":"ref17","first-page":"1062","volume-title":"Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor Ca<sup>2+<\/sup> release channel: case study of dantrolene","author":"Acsai","year":"2015"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2004.03658.x"},{"key":"ref19","volume-title":"Par Pharmaceutical, Inc. [Internet]"},{"key":"ref20","volume-title":"USWM [Internet]"},{"key":"ref21","volume-title":"USWM [Internet]"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/eja.0b013e3283439545"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1018178"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/eja.0b013e3283433b9f"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00787.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.12.022"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2007.00156.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704307"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0034-7094(12)70182-4"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.r112.349068"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-008-9133-4"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003996"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/343559a0"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.162761"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.43.26965"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-6147(00)89070-7"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198812000-00016"},{"key":"ref38","first-page":"275","volume-title":"Dantrolene dose response in awake man: implications for management of malignant hyperthermia","author":"Flewellen","year":"1983"},{"key":"ref39","volume-title":"National Institutes of Health [Internet]"},{"key":"ref40","volume-title":"Malignant Hyperthermia Association of the United States [Internet]"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.09.029"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-016-2305-z"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/aln.0000000000000257"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-021-01328-3"},{"key":"ref45","volume-title":"FDA approves eagle Pharmaceuticals\u2019 Ryanodex for the treatment of malignant hyperthermia [Internet]"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2014.66.2.153"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198504000-00028"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198603000-00006"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198405000-00001"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198702000-00028"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/0888-6296(88)90319-5"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/bf03015958"},{"key":"ref53","first-page":"442","volume-title":"A serious interaction of dantrolene and theophylline","author":"Tayeb","year":"1990"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1159\/000119626"},{"key":"ref55","volume-title":"Drugs.com [Internet]"},{"key":"ref56","first-page":"1115","volume-title":"Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States","author":"Brandom","year":"2011"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4065\/70.3.241"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3109\/01480548409014171"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1975.tb00862.x"},{"key":"ref60","first-page":"118","volume-title":"A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium-a skeletal muscle relaxant","author":"EllIs","year":"1976"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198904000-00013"},{"key":"ref62","first-page":"303","volume-title":"Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis","author":"Flewellen","year":"1980"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2010.06409.x"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(88)80147-9"},{"key":"ref65","first-page":"142","volume-title":"Oral muscle relaxants for the treatment of chronic pain associated with cerebral palsy","author":"Peck","year":"2020"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.03.002"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.40.9.1427"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-020-0934-0"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90301-1"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198703000-00013"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1975.03240200058032"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/0959-289x(95)82910-3"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198801000-00011"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199810000-00028"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.05.001"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800507"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.2.207"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2011-000155"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104343"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/aln.0000000000003224"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2000.440211.x"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1999.81.6.3054"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.5.34.x"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1089\/089771502753594909"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258543.45879.f5"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)90008-2"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199404000-00009"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2009.072892"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.03.035"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael078"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2021.19.1.1"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110543"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1097\/eja.0b013e32834c7c9d"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-021-00489-8"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/88.5.700"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1177\/0310057x9802600317"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1007\/bf01711537"},{"key":"ref99","first-page":"74","volume-title":"Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia: is there a link?","author":"Muldoon","year":"2008"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.168"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.91.5.1512"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.2.196"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125366"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.065"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1843632"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1021\/tx600260a"},{"key":"ref107","volume-title":"Procter &amp; Gamble Pharmaceuticals, TM Owner"},{"key":"ref108","volume-title":"Drug database; dantrolene sodium; Label\u2013supplement 49 [Internet]"}],"container-title":["Anesthesia and Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/anesth-pain-med.org\/upload\/pdf\/apm-22260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/anesth-pain-med.org\/journal\/view.php?doi=10.17085\/apm.22260","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/anesth-pain-med.org\/upload\/pdf\/apm-22260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T01:57:19Z","timestamp":1690509439000},"score":1,"resource":{"primary":{"URL":"http:\/\/anesth-pain-med.org\/journal\/view.php?doi=10.17085\/apm.22260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.17085\/apm.22260","relation":{},"ISSN":["1975-5171","2383-7977"],"issn-type":[{"value":"1975-5171","type":"print"},{"value":"2383-7977","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"2022-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}